Evidence map›Paper›PMID 41590698›Full record

ReviewMarine drugs2025

CRISPR-Cas Technology Turns

Amina Antonacci, Annalisa Masi, Vincenzo Vedi, Sara Colella, Federica Musella, Gabriella Fiorentino, Viviana Scognamiglio

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Marine drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Amina AntonacciInstitute of Crystallography, Department of Chemical Sciences and Materials Technologies, National Research Council, Via Salaria km 29.300, Monterotondo, 00015 Rome, Italy.ORCID 0000-0002-3245-3739
Annalisa MasiInstitute of Crystallography, Department of Chemical Sciences and Materials Technologies, National Research Council, Via Salaria km 29.300, Monterotondo, 00015 Rome, Italy.ORCID 0000-0002-7163-3978
Vincenzo VediInstitute of Crystallography, Department of Chemical Sciences and Materials Technologies, National Research Council, Via Salaria km 29.300, Monterotondo, 00015 Rome, Italy.ORCID 0009-0008-8452-3314
Sara ColellaInstitute of Crystallography, Department of Chemical Sciences and Materials Technologies, National Research Council, Via Salaria km 29.300, Monterotondo, 00015 Rome, Italy.
Federica MusellaDepartment of Biology, University of Naples Federico II, Complesso Universitario Monte S. Angelo, Via Cinthia 4, 80126 Naples, Italy.ORCID 0009-0000-5415-0539
Gabriella FiorentinoDepartment of Biology, University of Naples Federico II, Complesso Universitario Monte S. Angelo, Via Cinthia 4, 80126 Naples, Italy.ORCID 0000-0002-4089-3822
Viviana ScognamiglioInstitute of Crystallography, Department of Chemical Sciences and Materials Technologies, National Research Council, Via Salaria km 29.300, Monterotondo, 00015 Rome, Italy.ORCID 0000-0002-4932-8491

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microalgae represent some of the most promising eukaryotic platforms in biotechnology due to their rapid growth, simple cultivation requirements, reliance on sunlight as a primary energy source, and ability to synthesize high-value bioactive compounds. These characteristics have made microalgae attractive candidates in various fields, including biofuel production, carbon capture, and pharmaceutical development. However, several technical limitations have limited their large-scale use as sustainable biofactories. A paradigm shift is currently occurring thanks to the genetic manipulation of microalgae, driven by CRISPR-Cas technology. Significant progress has been made in the model species

Indexed as

BiotechnologyChlamydomonas reinhardtiiCRISPR-Cas SystemsMicroalgaeBiofuelsGene EditingMetabolic EngineeringBiofuelsadded-value compoundsbiotechnological applicationsChlamydomonas reinhardtiiCRISPR-Casgenome editingmicroalgae

Identifiers

PMID41590698
PMCPMC12842831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.